OABI
$3.42
$-0.01 (-0.29%)-0.29%
OpenLoading chart...
IndexN/A
Market Cap0.50B
Enterprise Value0.21B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-7.42
P/S11.26
P/B0.79
P/C-5.68
EV/EBITDA-4.60
EV/SalesN/A
EPS (ttm)-0.46
EarningsN/A
Gross Margin-18.17%
Oper. Margin-383.15%
Profit Margin-347.04%
Volume0.39M
Shs Outstand0.14B
Change-0.44%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M | $18.32M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M | $18.32M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $100.89M | $103.58M | $85.72M | $70.36M | $48.89M | $31.34M |
| Operating Income | $-74.50M | $-69.42M | $-26.65M | $-35.61M | $-25.62M | $-13.03M |
| Operating Margin | -282.30% | -203.19% | -45.11% | -102.48% | -110.12% | -71.12% |
| Net Income | $-62.03M | $-50.62M | $-22.33M | $-27.04M | $-17.56M | $-13.59M |
| Net Margin | -235.05% | -148.16% | -37.80% | -77.82% | -75.46% | -74.18% |
| EPS (Basic) | $-0.61 | $-0.51 | $-0.26 | $-0.24 | $-0.15 | $-0.12 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $325.56M | $375.23M | $421.21M | $304.46M | $295.38M | $262.32M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.94M | $60.64M | $79.84M | $70.16M | $59.84M | $44.13M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $287.62M | $314.58M | $341.37M | $234.31M | $235.54M | $218.19M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $287.62M | $314.58M | $341.37M | $234.31M | $235.54M | $218.19M |
| Total Liabilities & Stockholders Equity | $325.56M | $375.23M | $421.21M | $304.46M | $295.38M | $262.32M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-62.03M | $-50.62M | $-22.33M | $-27.04M | $-17.56M | $-13.59M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-39.66M | $2.35M | $-3.59M | $-5.67M | $3.62M | $-5.20M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development TimelinesGlobeNewswire Inc. AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now UnderwayBenzinga VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramGlobeNewswire Inc. USANA Health Sciences (USNA) Q1 Earnings and Revenues Top EstimatesZacks Investment Research Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are BuyingBenzinga Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?Zacks Investment Research
Show 12 more stories
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On TuesdayBenzinga 7 Hot Penny Stocks To Buy In May According To InsidersPennyStocks Stratasys, Navitas Semiconductor, United Insurance And Other Big Stocks Moving Higher On TuesdayBenzinga $1.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively BuyingBenzinga Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 EarningsZacks Investment Research Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023Benzinga Do Options Traders Know Something About OmniAb (OABI) Stock We Don't?Zacks Investment Research Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock UpZacks Investment Research Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023Benzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Discover more
You may be interested in